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COMMENTARY
Metastatic deaths in retinoblastoma 
patients treated with intraarterial chemotherapy 
(ophthalmic artery chemosurgery) worldwide
David H. Abramson1,2* , Carol L. Shields3, Pascal Jabbour4, Luiz Fernando Teixeira5, 
José Roberto Falco Fonseca6, Marcio Chaves Pedro Marques7, Francis L. Munier8, Francesco Puccinelli9, 
Theodora Hadjistilianou10, Sandra Bracco11, Guillermo Chantada12, Alejandro Ceciliano13 and Y. Pierre Gobin14
Abstract 
Background: Ophthalmic artery chemosurgery [OAC, intra-arterial chemotherapy (IAC)] was introduced in 2006 as 
treatment modality for intraocular retinoblastoma. The purpose of this commentary is to retrospectively review the 
incidence of metastatic deaths in retinoblastoma patients treated with OAC worldwide over a 10 year period. Retro-
spective data regarding metastatic deaths was collected from six international retinoblastoma centers (New York City 
USA, Philadelphia USA, Sao Paulo Brazil, Siena Italy, Lausanne Switzerland and Buenos Aires Argentina). All retinoblas-
toma patients from these centers (naive and recurrent, unilateral and bilateral) treated with OAC/IAC since 2006 have 
been included in this study. Data regarding number of patients, number of OAC/IAC infusions, number unilateral and 
bilateral, number treated for naive disease or salvage and number of metastatic deaths have been assessed. Over 
a 10-year period of time 1139 patients received OAC/IAC for 4396 infusions. At last follow-up there were only three 
metastatic deaths (all treated in Buenos Aires).
Conclusion: The current survey assessed the recorded risk of metastatic deaths in six retinoblastoma centers world-
wide in children with retinoblastoma (unilateral or bilateral) treated with OAC/IAC as primary or secondary therapy. 
Overall, the observed risk for metastatic deaths from retinoblastoma was <1% in OAC/IAC treated children.
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Background
For more than 100  years, ocular oncologists have been 
perfecting and attempting to find better alternatives 
to enucleation for management of intraocular retino-
blastoma. Small tumors without vitreous or subretinal 
seeding have been effectively treated with laser photoco-
agulation, thermotherapy, cryotherapy or brachytherapy 
without compromising patient survival from metastatic 
disease [1]. As far back as 1903 and continuing for almost 
90  years, external beam radiotherapy was the only way 
to salvage eyes with advanced intraocular disease [2]. 
While there were no randomized trials comparing radia-
tion to enucleation, it was universally recognized that 
conservative (non-enucleation) therapies lead to simi-
lar rates of metastatic death. In the 1990s, radiation was 
abandoned because of its impact on the development of 
second non-ocular cancers (which caused more deaths 
than primary retinoblastoma) [3] and was replaced 
with systemic chemotherapy [4]. In 1996, several papers 
described patients managed with systemic chemotherapy 
(with focal consolidation treatments) and they did not 
appear to have an increase in metastatic deaths (again-
no randomized trials were performed) but difficulty with 
tumor control for advanced disease with this technique 
lead to the development of intra-arterial chemother-
apy [IAC, ophthalmic artery chemosurgery (OAC)] for 
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advanced retinoblastoma. In some centers using IAC/
OAC, the enucleation rate has now dropped to 5% [5], 
but some authors have questioned if successful salvage of 
these eyes occurs with an increase in metastatic deaths 
from retinoblastoma [6]. Our six centers from the USA, 
Europe and Latin America have had extensive experience 
over a 10-year period with OAC/IAC and collaborated 
in the investigation of this query to report on the risk 
for metastatic deaths from retinoblastoma in children 
treated with IAC/OAC.
Survey
A retrospective survey of all patients treated with OAC/
IAC between May 2006 and November 1, 2016 from six 
Rb centers was performed. Metastatic death from ret-
inoblastoma was reported in addition to tumor lateral-
ity, number of cases treated with OAC/IAC, number 
of infusions delivered in each center and whether the 
patients received OAC/IAC as primary treatment (naïve) 
or secondary (after prior systemic chemotherapy and or 
radiotherapy). Each center used similar technique with 
combinations of Melphalan, Topotecan and Carboplatin, 
but there were minor variations in medication combina-
tions and number of cycles as this was a retrospective 
analysis.
Between May 1, 2006 and November 1, 2016, our six 
centers treated 1177 eyes of 1139 patients with 4396 sep-
arate OAC/IAC infusions. There were 781 unilateral and 
358 bilateral cases. There were 464 (39%) eyes that were 
naïve and 713 (61%) treated after prior systemic chemo-
therapy and/or radiation. Of these 1139 patients, there 
were 3 (<1%) who died from metastatic retinoblastoma 
(Table 1).
Discussion
Ophthalmic artery chemosurgery (OAC)/intra-arterial 
chemotherapy (IAC) has become an important tool for 
intraocular retinoblastoma management. This technique 
was first performed by Reese et  al. more than 60  years 
ago after delivering a nitrogen mustard derivative by 
direct puncture of the carotid artery. Despite a “dramatic” 
response, this strategy was abandoned because of com-
plications (including one death from carotid bleeding) 
and one death from neutropenia. Reese never reported 
on metastatic deaths in the 42 patients with retinoblas-
toma managed with carotid artery infusion.
Beginning more than 40  years ago, the Japanese per-
fected a technique they called “selective ophthalmic 
artery infusion (SOAI)” of chemotherapy using Melpha-
lan, a powerful alkylating agent that they had in  vitro 
determined was the most potent drug available for retin-
oblastoma. They reported on tumor control in a cohort of 
343 patients treated with several methods and found met-
astatic deaths in 8, 5 with metastases and 3 with direct 
or indirect extension into the central nervous system 
and death [7]. Unfortunately, it is impossible to know the 
exact treatment each child received because that report 
combined hundreds of retinoblastoma cases treated with 
external beam radiation, multiagent systemic chemother-
apy, intravitreal chemotherapy (Melphalan) and hyper-
thermia in addition to SOAI, with approximately 50% of 
these patients having all of the above treatments. Despite 
this, the authors compared established death rates from 
retinoblastoma in Japan and concluded that there was 
no increase in deaths attributable to SOAI. The Japanese 
study cannot be directly compared to the current survey 
since follow-up is much more long term.
The modern intra-arterial approach was introduced 
by two of us (DHA, YPG) in New York in May, 2006 [8]. 
Since that time it has been taught and adopted by nearly 
all the major retinoblastoma sites worldwide [9–11], and 
in a recent published worldwide survey chosen as the 
first line approach for unilateral advanced retinoblastoma 
[12]. Several major retinoblastoma centers employ OAC/
IAC for both naive and failed advanced eyes and in select 
cases where macula tumors threaten vision for both uni-
lateral and bilateral disease. While differences in choos-
ing indications for OAC/IAC exist, the technique, drugs, 
doses, frequency and catheters are generally the same 
in all centers [9]. With time and experience, we have 
achieved an eye salvage rate that improves with experi-
ence and now only 5–6% of all eyes with retinoblastoma 
are primarily enucleated as a result of using first line 
OAC/IAC and of those eyes treated 95% are retained [5, 
13]. The frequency of metastatic deaths in OAC treated 
children has been reported by many centers worldwide 
and a year ago our centers in New York, Philadelphia, 
Argentina and Switzerland reported on 634 cases with 
only one metastatic death [9].
A recent publication (from authors who had never done 
the procedure) has raised the question about metastatic 
deaths [6]. These authors also questioned if leaving an eye 
in with higher risk pathological features might preclude 
giving systemic chemotherapy and therefore compromise 
survival. Since OAC/IAC has become a transformative 
option for the management of retinoblastoma from the 
time of radiation, we decided to update our collective 
experience and include two additional experienced cent-
ers-from Italy and Brazil to expand our knowledge base. 
Table 1 Summary data from 6 centers of all patients treated 
with OAC between May 2006 and November 1, 2016
Patients Infusions Uni/bilat-
eral
First line 
(#eyes)
Salvage 
(# eyes)
Metastatic 
deaths
1139 4396 781/358 464 713 3
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There were no metastatic deaths from the two USA cent-
ers, two European centers or Brazil but 3 from the center 
in Argentina and they are instructive.
Case 1 Bilateral retinoblastoma with a positive fam-
ily history. The child was initially treated with systemic 
chemotherapy and progressed and received OAC. After 
progression intravitreal chemotherapy was given and 
then a second round of systemic chemotherapy which 
also failed. The family refused enucleation. Orbital inva-
sion and metastasis with death ensued.
Case 2 Bilateral retinoblastoma with a positive family 
history. One eye (International Classification E) refused 
enucleation and then refused systemic chemotherapy. 
The child was given OAC/IAC while social services 
worked to get consent for enucleation. Enucleation even-
tually performed and demonstrated scleral involvement 
and post laminar invasion. Family did not return for 
follow-up and then developed orbital disease that was 
treated with systemic chemotherapy but died after a CNS 
relapse.
Case 3 Bilateral retinoblastoma with a positive fam-
ily history. The child was initially treated with systemic 
chemotherapy and external beam irradiation. Because 
of progressive disease enucleation recommended but 
refused so OAC/IAC given. The disease progressed after 
treatment and enucleation was performed which showed 
disease at the cut margin of the optic nerve. Orbital and 
CNS invasion developed and later death.
Thus two of the deaths occurred in eyes previously 
treated with combinations of systemic chemotherapy 
and external beam irradiation and all deaths (2.6% of the 
patients treated in Argentina) occurred in families refus-
ing enucleation. This is comparable to the previously 
reported experience in the same hospital in the pre-OAC 
era (2.3%) [14]. Refusal of enucleation occurs more fre-
quently in less developed countries [15].
This report summarizes the 10-year experience from 
large retinoblastoma centers with experience with OAC/
IAC. Although the centers do not collaborate on a pro-
spective trial algorithm they are all using the same tech-
nique, doses, drugs and catheters introduced by us at 
Memorial Sloan Kettering Cancer Center and have all 
independently (and collectively) reported similar high 
ocular success rates. All metastatic deaths occurred in 
the Argentinian cohort and followed refusal of enuclea-
tion or poor follow up.
The finding that metastatic deaths from retinoblastoma 
are rare in patients treated with OAC/IAC is reassuring 
as this technique allows eyes that were previously enucle-
ated worldwide to be salvaged.
Conclusion
This retrospective survey reports on the incidence of 
metastatic deaths in retinoblastoma patients managed 
OAC/IAC. Over a 10-year period, children with retino-
blastoma (unilateral or bilateral) treated with OAC/IAC 
as primary or secondary therapy showed <1% risk for 
metastatic deaths from retinoblastoma.
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